Retatrutide is an investigational multi-receptor peptide agonist targeting GIP, GLP-1, and glucagon receptors , intended exclusively for controlled laboratory research related to obesity, glycemic regulation, and metabolic signaling pathways
The dosing of Wegovy typically starts at 0.25 mg once weekly and is intended to be gradually increased over time to minimize side effects and improve tolerability
This makes precise dosing even more critical because their bodies cannot compensate for dose changes the way a partially functioning thyroid might
Cherchi A, Lai C, Angelino F, Trucco G, Caponnetto S, Mereto PE, Rosolen G, Manzoli U, Schiavoni G, Reale A, Romeo F, Rizzon P, Sorgente L, Strano A, Novo S, Immordino R (1985) Effects of l-carnitine on exercise tolerance in chronic stable anginaa multicenter, double-blind, randomized, placebo controlled crossover study
Accordingly, we are unaware of any formally reported reference ranges in the literature
Medication for Obesity